<DOC>
	<DOCNO>NCT02022761</DOCNO>
	<brief_summary>This single centre , randomize , double-blind , placebo-controlled , single ascend dose study , safety pharmacokinetics laninamivir octanoate administer inhalation via TwinCaps® DPI assess adult mild moderate chronic asthma .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Inhaled Laninamivir Octanoate TwinCaps® DPI Adults With Chronic Asthma</brief_title>
	<detailed_description>32 subject , two sequential group 16 subject dose level ( 40 mg 80 mg ) , randomise 3:1 receive active drug match placebo . Males female age 18 65 year inclusive , mild moderate chronic asthma . Stratum 1 : Mild asthma - require treatment consistent Global Initiative Asthma ( GINA ) Step 2 Stratum 2 : Moderate asthma - require treatment consistent GINA Step 3 Following screen period 30 day , eligible consent subject admit clinic morning Day 1 . Laninamivir octanoate administer Day 1 . Subjects remain clinic Day 3 return subsequent outpatient visit Day 5 , Day 6 Day 7 . A final follow-up visit safety evaluation occur Day 14 ± 1 ( time premature discontinuation ) . Each subject participate study approximately 7 week .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>1 . Healthy male female subject 18 65 year age , inclusive 2 . Body mass index ( BMI ) within range 19.0 33.0 kg/m2 , inclusive screen 3 . Minimum weight 55.0 kg screen predose Day 1 4 . Clinical diagnosis asthma physician ≥12 month prior screen confirm write and/or medical record 5 . Mild asthmatic currently require treatment low dose inhale corticosteroid low intensity treatment OR Moderate asthmatic , require treatment low dose inhale corticosteroid longacting beta agonist , medium high dose inhaled corticosteroid alone low dose inhale corticosteroid low intensity treatment8 6 . Well control asthma 1 month prior dose define follow : 1 . Daytime symptom occur ≤8 times/ 4 week 2 . Daily activity limit asthma 3 . No nocturnal symptom result nighttime awakening 4 . Use shortacting betaagonist ( SABA ) ≤8 times/4 week treatment symptom 7 . There change asthma medication ( dose regimen ) within 4 week prior dose 8 . Preshortacting β2 agonist ( SABA ) force expiratory volume 1 second ( FEV1 ) ≥80 % predict normal value screen 9 . Nonsmokers least 6 month prior screen agrees smoke study 10 . Negative test result smoke status screening ( urine cotinine ) predose Day 1 ( Smokerlyser ) 11 . Female subject childbearing potential must practise true abstinence line prefer usual lifestyle subject ( Periodic abstinence , e.g . calendar , ovulation , symptothermal , postovulation method withdrawal acceptable method contraception ) , use willing continue use medically acceptable form birth control least 1 month prior screen ( least 3 month hormonal contraceptive ) least 1 month last study drug administration 12 . Male subject reproductive potential truly abstinent must use willing continue use medically acceptable contraceptive precaution screen least 1 month last study drug administration 13 . Female subject must negative serum pregnancy test screen negative urine pregnancy test predose Day 1 14 . Able speak , read , understand English sufficiently understand nature study , provide informed consent , allow completion study assessment 15 . Must provide write informed consent prior initiation protocolspecific procedures 1 . A history lifethreatening asthma exacerbation require intubation mechanical ventilation 2 . History severe asthma exacerbation last year require use systemic corticosteroid ( tablet , suspension injection ) 3 . Hospitalization visit ER asthma last year 4 . Intensive care admission asthma previous 5 year 5 . Any clinically significant abnormality clinical chemistry , haematology , urinalysis , judge investigator ( screen and/or Day 1 ) 6 . Clinically significant abnormality physical examination , medical history , 12lead ECG , vital sign , judge investigator ( screen predose Day 1 ) 7 . A QTcF &gt; 430 msec male subject &gt; 450 msec female subject ECG screen predose Day 1 8 . History presence clinically significant illness ( e.g. , cardiovascular , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic , musculoskeletal , psychiatric ) condition , opinion investigator would jeopardize safety subject validity study result 9 . History clinical evidence respiratory disease ( e.g. , COPD , cystic fibrosis ) 10 . Recent ( within 2 week ) current sign symptom respiratory infection screen predose Day 1 11 . Currently take theophylline take theophylline 3 month prior screen 12 . Use nonprescription drug within 3 day prior Day 1 13 . Use prescription medication ( except acceptable asthma medication , acceptable form birth control , hormone replacement ) recreational drug within 14 day prior Day 1 14 . Positive urine drug screen breath alcohol test screen predose Day 1 15 . Female subject pregnant lactate plan become pregnant within 30 day study drug administration 16 . History allergy , hypersensitivity , serious adverse reaction lactose neuraminidase inhibitor 17 . Previous exposure laninamivir octanoate 18 . Positive Hepatitis B surface antigen , Hepatitis C virus antibody , Human Immunodeficiency Virus ( HIV ) p24 antigen/antibodies screen 19 . Donation loss ≥500 mL whole blood within 2 month prior Day 1 20 . Current pending legal charge currently probation , base subject report 21 . Receipt investigational product clinical trial within 30 day 5 halflives , whichever longer , prior Day 1 22 . Concurrent enrolment type medical research , judge investigator scientifically medically compatible study 23 . An employee sponsor research site personnel directly affiliate study immediate family member define spouse , parent , sibling , child , whether biological legally adopt 24 . A subject , opinion investigator , consider suitable unlikely comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Mild moderate asthmatic</keyword>
	<keyword>Adults</keyword>
	<keyword>Laninamivir</keyword>
</DOC>